Sample Size Efficiency of 4-Period, 2-Seq, 2-Formulation Design [RSABE / ABEL]

posted by Helmut Homepage – Vienna, Austria, 2022-01-28 22:06 (759 d 16:52 ago) – Posting: # 22758
Views: 1,385

Hi Sereng,

❝ […] The PSG also asks us to use the RSABE approach for properly adjusting the BE acceptance criteria based on "reference variability…


So far so good.

❝ … and comparing test and referenced product within-subject variability".


That’s rather unusual. Can you post a link to the guidance?

❝ Can we safely assume that conducting such a replicate study would (at least) reduce our sample size by 50% over a 2-Period, 2-Sequence, 2-Formulation BE study?


No, that’s wrong. See there.

❝ […] would there be any additional sample size efficiency arising from the use of the RSABE?


The idea behind RSABE is to maintain power independent from the CV.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,912 posts in 4,806 threads, 1,636 registered users;
20 visitors (0 registered, 20 guests [including 4 identified bots]).
Forum time: 14:59 CET (Europe/Vienna)

It is the peculiar and perpetual error of the human understanding
to be more moved and excited by affirmatives than negatives.    Francis Bacon

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5